Pablo is the founder, CEO and Chairman of Royalty Pharma (Nasdaq: RPRX). Since its founding in 1996, Royalty Pharma has been a pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies.

Pablo co-founded Pharmakon Advisors which has become the premier provider of debt capital to the life sciences industry and is also a co-founder of several biotech companies: ProKidney (Nasdaq: PROK), Sequel Med-tech, ITB-MED, ChoironeX and POD.

Pablo is the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America and serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, the Hospital for Special Surgery, Pasteur Foundation (US), the OMI and Park Avenue Armory. Pablo and his wife Almudena created the Legorreta Center for Clinical Transplant Tolerance at MGH and the Legorreta Cancer Center at Brown University.